^
Association details:
| Biomarker: | TMB-H + PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
490 - A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC
Published date:
03/10/2021
Excerpt:
TMB cut-off for objective response rate (ORR) in two independent cohorts (DFCI and MSKCC) of pts with NSCLC treated with ICI....A TMB ≥90th percentile correlated with longer PFS/OS among NSCLCs...longer PFS among those with PD-L1 <1% (Table).
